This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Looking for a Growth Stock? 3 Reasons Why Universal Health Services (UHS) is a Solid Choice
by Zacks Equity Research
Universal Health Services (UHS) possesses solid growth attributes, which could help it handily outperform the market.
HCA Healthcare (HCA) Rises 24.8% in a Year: More Room to Run?
by Zacks Equity Research
HCA Healthcare's (HCA) growing equivalent admissions are supporting performance.
Here's Why Universal Health Services (UHS) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Industry Outlook Highlights HCA Healthcare, Universal Health Services and Tenet Healthcare
by Zacks Equity Research
HCA Healthcare, Universal Health Services and Tenet Healthcare have been highlighted in this Industry Outlook article.
Can Universal Health Services (UHS) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Universal Health Services (UHS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Universal Health Services (UHS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Universal Health Services (UHS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Stocks Worth a Deeper Dive in the Thriving Hospital Industry
by Kaibalya Pravo Dey
Following a careful analysis of the Zacks Medical-Hospital industry, we advise focusing on companies like HCA, UHS and THC.
Universal Health Services (UHS) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Universal Health Services (UHS) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Universal Health (UHS) Q4 Earnings Beat on Adjusted Admissions
by Zacks Equity Research
Universal Health (UHS) expects net revenues between $15.411 billion and $15.706 billion for 2024, which indicates 8.9% year-over-year growth.
Compared to Estimates, Universal Health Services (UHS) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Universal Health Services (UHS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Universal Health Services (UHS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 3.64% and 1.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Cooper Companies (COO) in Q1 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement in both the Dental and Animal Health segments.
What's in Store for DENTSPLY SIRONA (XRAY) in Q4 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) fourth-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Should You Buy Universal Health (UHS) Ahead of Earnings?
by Zacks Equity Research
Universal Health (UHS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Universal Health Services, Inc. (UHS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Universal Health Services (UHS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) fourth-quarter results are likely to reflect improved performances from the Acute Care Hospital Services and Behavioral Health Care Services businesses.
Ahead of Universal Health Services (UHS) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Universal Health Services (UHS) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Masimo (MASI), UCHealth Unite to Improve Care With Telehealth
by Zacks Equity Research
Masimo (MASI) collaborates with UCHealth to boost patient care by combining its latest virtual care technologies with UCHealth's clinical expertise and telehealth innovations.
Is Universal Health Services (UHS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Boston Scientific (BSX) Completes First Case With Its PFA System
by Zacks Equity Research
Boston Scientific (BSX) announces the completion of its first commercial cases with its FDA-cleared Farapulse PFA System in the United States.
Universal Health Services (UHS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Universal Health Services (UHS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merit Medical's (MMSI) SCOUT Guidance System Gets FDA Nod
by Zacks Equity Research
Merit Medical's (MMSI) SCOUT MD Surgical Guidance System receives FDA clearance, which aims to boost the treatment of breast cancer by increasing accuracy to target tumor sites.
AngioDynamics (ANGO) Divests Its PICC & Midline Businesses
by Zacks Equity Research
AngioDynamics (ANGO) finalizes its PICC and Midline businesses divestment to Spectrum Vascular to optimize its product portfolio and to focus on strengthening its med tech segment.